Heejin Kim

BD Lead at Prazer Therapeutics

Presenter

Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).